Comi G, Filippi M, Rovaris M, Leocani L, Medaglini S, Locatelli T
Department of Clinical Neurophysiology, University of Milan, Scientific Institute H San Raffaele, Italy.
J Neurol Neurosurg Psychiatry. 1998 May;64 Suppl 1:S21-5.
Magnetic resonance imaging (MRI) has a pivotal role in diagnosis of multiple sclerosis and is being increasingly used as a paraclinical measure to assess treatment efficacy in clinical trials. However, the correlations between clinical and MRI findings in patients with multiple sclerosis are weak and, therefore, newer MR techniques are being developed to increase both MRI sensitivity for detecting disease activity and its pathological specificity for better assessing disease evolution. Evoked potentials (EPs) can be used to confirm the diagnosis of multiple sclerosis and their abnormalities are correlated with symptoms and signs referable to involvement of the corresponding nervous pathways. However, their use is limited when assessing disease progression and monitoring clinical trials in multiple sclerosis. Both magnetic resonance imaging (MRI) and evoked potentials (EPs) provide information which cannot be obtained by clinical evaluation, especially for assessing disease activity. Nevertheless, both these paraclinical techniques cannot substitute for clinical measures of disability when assessing disease progression and monitoring phase III clinical trials in multiple sclerosis.
磁共振成像(MRI)在多发性硬化症的诊断中起着关键作用,并且在临床试验中越来越多地被用作评估治疗效果的辅助临床手段。然而,多发性硬化症患者的临床症状与MRI表现之间的相关性较弱,因此,人们正在开发更新的MR技术,以提高MRI检测疾病活动的敏感性及其病理特异性,从而更好地评估疾病进展。诱发电位(EPs)可用于确诊多发性硬化症,其异常与相应神经通路受累相关的症状和体征有关。然而,在评估多发性硬化症的疾病进展和监测临床试验时,其应用受到限制。磁共振成像(MRI)和诱发电位(EPs)都能提供临床评估无法获得的信息,特别是在评估疾病活动方面。然而,在评估多发性硬化症的疾病进展和监测III期临床试验时,这两种辅助临床技术都不能替代残疾的临床测量指标。